203,740 Shares in Voyager Therapeutics, Inc. $VYGR Purchased by Altshuler Shaham Ltd

Altshuler Shaham Ltd purchased a new position in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 203,740 shares of the company’s stock, valued at approximately $801,000. Altshuler Shaham Ltd owned 0.37% of Voyager Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also bought and sold shares of the business. AQR Capital Management LLC grew its stake in Voyager Therapeutics by 179.3% during the first quarter. AQR Capital Management LLC now owns 495,260 shares of the company’s stock worth $1,674,000 after buying an additional 317,927 shares in the last quarter. Acadian Asset Management LLC boosted its stake in shares of Voyager Therapeutics by 863.3% in the 1st quarter. Acadian Asset Management LLC now owns 230,708 shares of the company’s stock valued at $778,000 after purchasing an additional 206,758 shares in the last quarter. Two Sigma Investments LP acquired a new stake in shares of Voyager Therapeutics in the 3rd quarter valued at approximately $657,000. Hsbc Holdings PLC boosted its stake in shares of Voyager Therapeutics by 118.5% in the 2nd quarter. Hsbc Holdings PLC now owns 148,377 shares of the company’s stock valued at $440,000 after purchasing an additional 80,474 shares in the last quarter. Finally, Erste Asset Management GmbH boosted its stake in shares of Voyager Therapeutics by 7.0% in the 4th quarter. Erste Asset Management GmbH now owns 1,195,141 shares of the company’s stock valued at $4,718,000 after purchasing an additional 78,348 shares in the last quarter. 48.03% of the stock is owned by institutional investors.

Voyager Therapeutics Stock Performance

Voyager Therapeutics stock opened at $3.62 on Thursday. Voyager Therapeutics, Inc. has a 52-week low of $2.83 and a 52-week high of $5.55. The firm has a 50 day moving average price of $3.81 and a two-hundred day moving average price of $3.93. The firm has a market cap of $218.72 million, a price-to-earnings ratio of -1.84 and a beta of 1.25.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.07. The firm had revenue of $1.19 million during the quarter, compared to analyst estimates of $8.79 million. Voyager Therapeutics had a negative net margin of 319.61% and a negative return on equity of 55.97%. As a group, equities research analysts predict that Voyager Therapeutics, Inc. will post -1.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

VYGR has been the topic of a number of research analyst reports. Wall Street Zen downgraded shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Truist Financial upgraded shares of Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. HC Wainwright restated a “buy” rating on shares of Voyager Therapeutics in a research note on Tuesday, May 26th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Voyager Therapeutics in a research note on Wednesday, April 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Voyager Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $16.50.

Insider Transactions at Voyager Therapeutics

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 11,511 shares of Voyager Therapeutics stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $3.87, for a total transaction of $44,547.57. Following the transaction, the chief executive officer directly owned 472,549 shares of the company’s stock, valued at $1,828,764.63. The trade was a 2.38% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 12.70% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.